Erytech Pharma – About the Company
Erytech is testing GRASPA in three ongoing clinical trials. A European Phase III trial in relapsed adults and children with acute lymphoblastic leukemia (ALL) is expected to be completed in the third quarter of 2014. A Phase I/II trial with adult ALL patients is ongoing in the US, and a European Phase IIb trial in elderly AML patients received a positive Data and Safety Monitoring Board review in November 2013. Erytech is also planning a Phase II trial with GRASPA in pancreatic cancer that is expected to launch in the second quarter of 2014. Additional uses of the RBC technology are under preclinical investigation and include cancer vaccination and immune tolerance applications.